Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $238.81, for a total value of $859,716.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $31,045.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $1.05 during trading hours on Thursday, reaching $235.95. The stock had a trading volume of 391,825 shares, compared to its average volume of 439,210. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $261.54. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The business’s fifty day moving average is $233.36 and its two-hundred day moving average is $228.79. The company has a market cap of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same period last year, the firm earned $2.67 EPS. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of the stock. Vontobel Holding Ltd. grew its position in United Therapeutics by 15.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 1,920 shares of the biotechnology company’s stock worth $434,000 after acquiring an additional 260 shares during the last quarter. Asset Management One Co. Ltd. increased its holdings in shares of United Therapeutics by 2.8% in the third quarter. Asset Management One Co. Ltd. now owns 22,968 shares of the biotechnology company’s stock valued at $5,188,000 after purchasing an additional 633 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of United Therapeutics by 8.2% during the third quarter. Handelsbanken Fonder AB now owns 7,900 shares of the biotechnology company’s stock valued at $1,784,000 after acquiring an additional 600 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in United Therapeutics by 9.4% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 16,250 shares of the biotechnology company’s stock worth $3,664,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Atwood & Palmer Inc. boosted its stake in shares of United Therapeutics by 1.0% in the 3rd quarter. Atwood & Palmer Inc. now owns 59,569 shares of the biotechnology company’s stock valued at $13,455,000 after purchasing an additional 580 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the company from $213.00 to $215.00 in a report on Monday, February 12th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Wedbush reaffirmed an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $294.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.